ARCHIVES

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

This article is from The Cancer Letter archive.

Vol. 30 No. 19 | May 7, 2004

Download PDF Visit The Full Archive

Related Articles

TCGA Researchers Discover Stomach Cancer Falls Into Four Distinct Molecular Subtypes

August 29, 2014

ACS Executive Proposes Efficiency Plan, Critics Fear Erosion Of Local Influence

May 1, 1998

“Triple-Negative” Should Be Split Into Subtypes, Say Researchers

February 22, 2013

NIH Spent $181.3 Million on PR Last Year; House Probe Prompts Analysis of Spending

July 12, 2013

Bunn Says ASCO Is “Strong, Diverse, Respected, Growing”

June 6, 2003

NIH Limits Salaries On Grants, Contracts ACS Clinical Awards Available For 1995

February 25, 1994